Viral hepatitis is among the most prevalent and vital diseases contributing to high global mortality and disability (
1). The 2024 global hepatitis report from the World Health Organization (WHO) indicates a rise in fatalities attributed to viral hepatitis. The disease leads to 1.3 million deaths each year, ranking it as the second most lethal infection worldwide, similar to tuberculosis (
2).
Currently, there are five main types of viral hepatitis (
3). The majority of the global burden of viral hepatitis is induced by the hepatitis A, B, C, D, and E viruses (
3,
4). The primary viral hepatitis types are A, B, and C (
5). Another type, hepatitis E, was first identified in 1978 during an epidemic in the Kashmir Valley of India, where 52,000 individuals were affected, leading to the death of 1,700 people (
6).
Hepatitis A is an infectious disease caused by the hepatitis A virus (HAV), which belongs to the Picornaviridae family and especially occurs in countries characterized by low socioeconomic status and inadequate sanitation (
7). Hepatitis E virus (HEV), a member of the family Hepeviridae (
8), leads to a viral disease similar to HAV (
9). The causative agents of these two viral diseases lack an envelope and have a positive-sense single-stranded RNA (ssRNA) genome (
10-
12). The HAV and HEV both cause acute liver diseases and are typically transmitted through the fecal-oral route via contaminated food and water, as well as person-to-person contact (
3,
9,
13,
14). Following an incubation period of approximately 28 days (15 - 50 days) for HAV and 40 days (15 - 60 days) for HEV, these viruses can lead to either clinical illness or remain asymptomatic in individuals (
7,
15,
16). Hepatitis A continues to be self-limiting and does not develop into a chronic liver condition. The acute phase of the disease is characterized by the presence of hepatitis A-specific IgM antibodies in the serum (
17). A more recent nationwide study on the seroprevalence rate of HAV in the Iranian population indicated that out of 5,419 participants from 12 provinces of Iran, 3,603 (66.5%) of people were seropositive for HAV-immunoglobulin G (IgG), which shows that vaccination against HAV is needed, at least for high-risk people (
18). Additionally, the predicted outbreak of HEV in Iran is around 10%, which is noteworthy due to the virus's characteristics (
19). While a vaccine for HAV is already available and has led to a significant reduction in the prevalence of the disease, several vaccines for HEV are currently being developed, with some already available in China, showing promising results (
20). The HEV is the only zoonotic virus among the different types of hepatitis viruses. It is shown that there are abundant animal reservoirs for HEV, including pigs, chickens, rabbits, sheep, and others, which makes HEV a unique hepatitis infection (
21). Pregnant women are the highest-risk group for HEV infection, with a mortality rate of up to 25% reported in this population (
13,
20,
22). Furthermore, the mortality rate rises in pregnant cases of fulminant hepatitis (
23). However, hepatitis A infection is rarely reported in pregnancy compared to HEV and shows a low mortality rate of 0.1 - 2.1% (
13,
20). Conversely, both have similar mortality rates (0.1 - 4%) among the general population (
13,
20). Therefore, HAV and HEV pose special problems to public hygiene (
20). Unfortunately, few studies in Iran report the seroepidemiology of these two viruses in the general population. Moreover, Ardabil, a province in the northwest of Iran, has a high incidence of gastrointestinal diseases such as gastric cancer due to various factors contaminating the digestive system (
24), and the seroprevalence of hepatitis A and E, as intestinal hepatitis infections, is undetermined in this region.